EVLO | Evelo Biosciences, Inc. | [NASD]
Index- P/E- EPS (ttm)-1.13 Insider Own0.10% Shs Outstand110.91M Perf Week-0.72%
Market Cap14.54M Forward P/E- EPS next Y-0.72 Insider Trans-64.82% Shs Float106.41M Perf Month-24.71%
Income-110.00M PEG- EPS next Q-0.17 Inst Own83.30% Short Float / Ratio3.35% / 0.96 Perf Quarter-75.74%
Sales- P/S- EPS this Y43.10% Inst Trans2.73% Short Interest3.57M Perf Half Y-92.50%
Book/sh-0.25 P/B- EPS next Y-4.30% ROA-144.40% Target Price1.40 Perf Year-91.59%
Cash/sh0.29 P/C0.53 EPS next 5Y- ROE- 52W Range0.02 - 3.29 Perf YTD-90.60%
Dividend- P/FCF- EPS past 5Y-4.20% ROI- 52W High-95.40% Beta1.27
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low523.05% ATR0.03
Employees66 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)47.92 Volatility13.72% 15.47%
OptionableYes Debt/Eq- EPS Q/Q59.00% Profit Margin- Rel Volume0.29 Prev Close0.13
ShortableYes LT Debt/Eq- EarningsMar 16 BMO Payout- Avg Volume3.73M Price0.15
Recom3.20 SMA2010.69% SMA50-10.92% SMA200-88.44% Volume1,094,421 Change17.27%
Date Action Analyst Rating Change Price Target Change
Nov-01-21Upgrade Chardan Capital Markets Neutral → Buy $12
Jun-23-21Initiated Cantor Fitzgerald Overweight $28
Apr-12-21Upgrade Jefferies Hold → Buy $11 → $18
Dec-23-20Initiated JMP Securities Mkt Outperform $27
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
May-12-20Downgrade Jefferies Buy → Hold $18 → $6
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
May-17-23 12:00PM
May-16-23 06:00AM
May-10-23 08:42AM
Apr-26-23 03:51PM
07:30AM Loading…
Mar-20-23 10:46PM
Mar-16-23 10:23PM
Mar-09-23 06:00AM
Mar-01-23 09:35AM
Feb-27-23 06:00AM
Feb-13-23 09:35AM
Feb-01-23 01:56PM
12:53PM Loading…
Jan-24-23 06:48AM
Jan-11-23 04:15PM
Dec-16-22 06:01AM
Dec-01-22 07:40AM
Nov-15-22 04:01PM
Nov-14-22 05:27PM
Nov-08-22 06:00AM
Sep-07-22 01:00AM
Sep-01-22 05:15PM
Aug-11-22 11:00PM
06:00AM Loading…
Aug-08-22 09:33AM
Aug-05-22 06:00AM
Jul-18-22 06:00AM
Jun-24-22 08:01AM
May-25-22 08:37AM
May-12-22 10:47AM
Apr-21-22 06:00AM
Apr-14-22 11:22AM
Apr-06-22 06:00AM
Mar-26-22 12:00PM
Mar-24-22 01:30PM
Mar-17-22 07:00AM
Mar-07-22 06:00AM
Mar-02-22 08:50AM
Feb-28-22 09:00AM
Feb-24-22 07:55AM
Feb-17-22 07:00AM
Feb-15-22 10:05AM
Feb-11-22 12:00PM
Feb-07-22 07:00AM
Jan-17-22 07:00AM
Jan-04-22 07:00AM
Dec-14-21 07:00AM
Nov-09-21 07:00AM
Oct-28-21 07:01PM
Oct-21-21 07:00AM
Oct-18-21 08:49AM
Oct-13-21 10:47AM
Sep-29-21 03:37AM
Sep-28-21 12:38PM
Sep-27-21 12:11PM
Sep-20-21 07:00AM
Sep-09-21 07:00AM
Sep-08-21 08:30AM
Sep-07-21 07:00AM
Aug-06-21 08:46AM
Jul-31-21 05:31AM
Jul-29-21 07:00AM
Jul-22-21 07:00AM
Jul-14-21 04:01PM
Jun-21-21 06:50PM
Jun-16-21 04:01PM
Jun-03-21 04:01PM
Jun-01-21 07:00AM
May-26-21 07:00AM
May-25-21 06:00AM
May-19-21 09:01AM
May-13-21 07:00AM
Apr-30-21 03:59PM
Apr-29-21 03:01PM
Apr-22-21 07:00AM
Apr-20-21 04:01PM
Apr-19-21 05:50AM
Apr-15-21 07:00AM
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bodmer MarkCSO, President of R&DMay 08Sale0.1368,0148,536285,128May 10 09:31 PM
McHale DuncanChief Medical OfficerMay 08Sale0.1366,7308,37597,516May 10 09:32 PM
Thorell MarellaChief Financial OfficerMay 08Sale0.1338,5314,83691,469May 10 09:31 PM
GILL SIMBAPresident & CEOMay 08Sale0.133,53744458,512May 10 09:31 PM
CARRIERE STEPHEN JPrincipal Accounting OfficerJan 23Sale1.06151160203Jan 23 05:35 PM
Epstein David RDirectorJun 30Option Exercise0.004,927093,932Jun 30 04:52 PM
Epstein David RDirectorMay 31Option Exercise0.004,925089,005Jun 01 04:12 PM